M1 KLINIKEN AG (M12.DE) Stock Fundamental Analysis
FRA:M12 - Deutsche Boerse Ag - DE000A0STSQ8 - Common Stock - Currency: EUR
Overall M12 gets a fundamental rating of 6 out of 10. We evaluated M12 against 25 industry peers in the Health Care Providers & Services industry. While M12 has a great health rating, its profitability is only average at the moment. M12 is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings would make M12 suitable for growth investing!
1. Profitability
1.1 Basic Checks
In the past year M12 was profitable.
M12 had a positive operating cash flow in the past year.
Each year in the past 5 years M12 has been profitable.
Each year in the past 5 years M12 had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 8.27%, M12 belongs to the top of the industry, outperforming 92.00% of the companies in the same industry.
M12's Return On Equity of 15.32% is fine compared to the rest of the industry. M12 outperforms 72.00% of its industry peers.
M12 has a Return On Invested Capital of 10.98%. This is amongst the best in the industry. M12 outperforms 92.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for M12 is in line with the industry average of 6.33%.
The last Return On Invested Capital (10.98%) for M12 is above the 3 year average (5.33%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.27% | ||
| ROE | 15.32% | ||
| ROIC | 10.98% |
ROA(3y)3.84%
ROA(5y)5.12%
ROE(3y)7.69%
ROE(5y)9.05%
ROIC(3y)5.33%
ROIC(5y)5.06%
1.3 Margins
M12 has a better Profit Margin (5.03%) than 68.00% of its industry peers.
In the last couple of years the Profit Margin of M12 has declined.
M12 has a Operating Margin (6.87%) which is in line with its industry peers.
M12's Operating Margin has declined in the last couple of years.
M12's Gross Margin of 17.41% is on the low side compared to the rest of the industry. M12 is outperformed by 64.00% of its industry peers.
M12's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.87% | ||
| PM (TTM) | 5.03% | ||
| GM | 17.41% |
OM growth 3Y19.76%
OM growth 5Y-14.29%
PM growth 3Y-8.75%
PM growth 5Y-20.36%
GM growth 3Y-11.67%
GM growth 5Y-14.71%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), M12 is creating some value.
The number of shares outstanding for M12 has been reduced compared to 1 year ago.
M12 has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, M12 has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 4.72 indicates that M12 is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.72, M12 belongs to the top of the industry, outperforming 96.00% of the companies in the same industry.
The Debt to FCF ratio of M12 is 0.60, which is an excellent value as it means it would take M12, only 0.60 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.60, M12 belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
M12 has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
M12 has a better Debt to Equity ratio (0.07) than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.6 | ||
| Altman-Z | 4.72 |
ROIC/WACC1.59
WACC6.91%
2.3 Liquidity
M12 has a Current Ratio of 1.76. This is a normal value and indicates that M12 is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.76, M12 is in the better half of the industry, outperforming 76.00% of the companies in the same industry.
A Quick Ratio of 1.10 indicates that M12 should not have too much problems paying its short term obligations.
With a decent Quick ratio value of 1.10, M12 is doing good in the industry, outperforming 76.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.76 | ||
| Quick Ratio | 1.1 |
3. Growth
3.1 Past
M12 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 163.63%, which is quite impressive.
Measured over the past 5 years, M12 shows a small growth in Earnings Per Share. The EPS has been growing by 5.87% on average per year.
Looking at the last year, M12 shows a quite strong growth in Revenue. The Revenue has grown by 12.05% in the last year.
Measured over the past years, M12 shows a very strong growth in Revenue. The Revenue has been growing by 37.14% on average per year.
EPS 1Y (TTM)163.63%
EPS 3Y12.51%
EPS 5Y5.87%
EPS Q2Q%189.66%
Revenue 1Y (TTM)12.05%
Revenue growth 3Y25.61%
Revenue growth 5Y37.14%
Sales Q2Q%11.24%
3.2 Future
Based on estimates for the next years, M12 will show a very strong growth in Earnings Per Share. The EPS will grow by 39.45% on average per year.
M12 is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.75% yearly.
EPS Next Y89.39%
EPS Next 2Y47.84%
EPS Next 3Y39.45%
EPS Next 5YN/A
Revenue Next Year12.2%
Revenue Next 2Y9.24%
Revenue Next 3Y8.84%
Revenue Next 5Y7.75%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 15.88, M12 is valued correctly.
The rest of the industry has a similar Price/Earnings ratio as M12.
M12's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.25.
With a Price/Forward Earnings ratio of 13.91, M12 is valued correctly.
M12's Price/Forward Earnings ratio is in line with the industry average.
M12's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.15.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.88 | ||
| Fwd PE | 13.91 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as M12.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of M12 indicates a somewhat cheap valuation: M12 is cheaper than 68.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.57 | ||
| EV/EBITDA | 9.64 |
4.3 Compensation for Growth
M12's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of M12 may justify a higher PE ratio.
A more expensive valuation may be justified as M12's earnings are expected to grow with 39.45% in the coming years.
PEG (NY)0.18
PEG (5Y)2.71
EPS Next 2Y47.84%
EPS Next 3Y39.45%
5. Dividend
5.1 Amount
M12 has a Yearly Dividend Yield of 3.53%.
Compared to an average industry Dividend Yield of 2.77, M12 pays a better dividend. On top of this M12 pays more dividend than 92.00% of the companies listed in the same industry.
M12's Dividend Yield is a higher than the S&P500 average which is at 2.40.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.53% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y47.84%
EPS Next 3Y39.45%
FRA:M12 (5/30/2025, 7:00:00 PM)
13.5
-0.66 (-4.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners1.43%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap265.14M
Analysts85
Price Target26.52 (96.44%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.53% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.45%
PT rev (3m)-5.45%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)0.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.88 | ||
| Fwd PE | 13.91 | ||
| P/S | 0.8 | ||
| P/FCF | 7.57 | ||
| P/OCF | 7.31 | ||
| P/B | 2.42 | ||
| P/tB | 12.27 | ||
| EV/EBITDA | 9.64 |
EPS(TTM)0.85
EY6.3%
EPS(NY)0.97
Fwd EY7.19%
FCF(TTM)1.78
FCFY13.21%
OCF(TTM)1.85
OCFY13.68%
SpS16.97
BVpS5.57
TBVpS1.1
PEG (NY)0.18
PEG (5Y)2.71
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.27% | ||
| ROE | 15.32% | ||
| ROCE | 15.68% | ||
| ROIC | 10.98% | ||
| ROICexc | 12.98% | ||
| ROICexgc | 44.89% | ||
| OM | 6.87% | ||
| PM (TTM) | 5.03% | ||
| GM | 17.41% | ||
| FCFM | 10.51% |
ROA(3y)3.84%
ROA(5y)5.12%
ROE(3y)7.69%
ROE(5y)9.05%
ROIC(3y)5.33%
ROIC(5y)5.06%
ROICexc(3y)7.46%
ROICexc(5y)7.66%
ROICexgc(3y)20.1%
ROICexgc(5y)16.58%
ROCE(3y)7.61%
ROCE(5y)7.23%
ROICexcg growth 3Y47.1%
ROICexcg growth 5Y10.13%
ROICexc growth 3Y26.66%
ROICexc growth 5Y-7.94%
OM growth 3Y19.76%
OM growth 5Y-14.29%
PM growth 3Y-8.75%
PM growth 5Y-20.36%
GM growth 3Y-11.67%
GM growth 5Y-14.71%
F-Score8
Asset Turnover1.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.6 | ||
| Debt/EBITDA | 0.26 | ||
| Cap/Depr | 24.28% | ||
| Cap/Sales | 0.37% | ||
| Interest Coverage | 16.74 | ||
| Cash Conversion | 129.38% | ||
| Profit Quality | 209.01% | ||
| Current Ratio | 1.76 | ||
| Quick Ratio | 1.1 | ||
| Altman-Z | 4.72 |
F-Score8
WACC6.91%
ROIC/WACC1.59
Cap/Depr(3y)24.3%
Cap/Depr(5y)28.94%
Cap/Sales(3y)0.45%
Cap/Sales(5y)0.8%
Profit Quality(3y)264.65%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)163.63%
EPS 3Y12.51%
EPS 5Y5.87%
EPS Q2Q%189.66%
EPS Next Y89.39%
EPS Next 2Y47.84%
EPS Next 3Y39.45%
EPS Next 5YN/A
Revenue 1Y (TTM)12.05%
Revenue growth 3Y25.61%
Revenue growth 5Y37.14%
Sales Q2Q%11.24%
Revenue Next Year12.2%
Revenue Next 2Y9.24%
Revenue Next 3Y8.84%
Revenue Next 5Y7.75%
EBIT growth 1Y86.59%
EBIT growth 3Y50.43%
EBIT growth 5Y17.54%
EBIT Next Year104.26%
EBIT Next 3Y33.75%
EBIT Next 5Y41.71%
FCF growth 1Y68.01%
FCF growth 3Y71.63%
FCF growth 5Y106.11%
OCF growth 1Y62.27%
OCF growth 3Y57.15%
OCF growth 5Y48.73%